Matt Bottomley

Pablo Zuanic

Vivien Azer

- InterCure reported **NIS 130 million in revenue** for the first half of 2025, an increase of **3%** compared to the first half of 2024.  **[1857030_fb4158e3005c4e2d8a846b1c1d61140c_0]** 
- The company achieved **NIS 12.6 million in Adjusted EBITDA** and generated **NIS 12 million in positive operating cash flow** during the first half of 2025.  **[1857030_fb4158e3005c4e2d8a846b1c1d61140c_0]** 
- InterCure recorded a **net loss of NIS 1.8 million** for the first half of 2025, and had **NIS 54 million in cash on hand** as of June 30, 2025.  **[1857030_fb4158e3005c4e2d8a846b1c1d61140c_0]** 
- The company signed an agreement in September 2025 to acquire **Botanico Ltd. (ISHI)**, a strategic move expected to enhance access to premium U.S. genetics and international market opportunities, while also monitoring U.S. cannabis rescheduling developments.  **[1857030_fb4158e3005c4e2d8a846b1c1d61140c_1]**

InterCure Reports First Half 2025 Results

- **InterCure Ltd.** reported **NIS 130 million** in revenue for the first half of 2025, marking a **3%** increase compared to the first half of 2024.  **[1857030_0001493152-25-017373_ex99-1.htm:0]** 
- The company achieved **NIS 12 million** in positive operating cash flow, a significant improvement from **negative NIS 43 million** in the first half of 2024.  **[1857030_0001493152-25-017373_ex99-1.htm:0]** 
- Net loss for the period was **NIS 1.8 million**, compared to near break-even in the first half of 2024, with Adjusted EBITDA reaching **NIS 12.6 million**.  **[1857030_0001493152-25-017373_ex99-1.htm:0]** 
- InterCure received **NIS 81 million** in compensation advances from Israeli authorities for war-related damages, out of a total submitted claim of **NIS 251 million**.  **[1857030_0001493152-25-017373_ex99-1.htm:1]** 
- In September 2025, the company signed an agreement to acquire Botanico Ltd. (ISHI), a strategic move to enhance access to U.S. genetics and international market opportunities.  **[1857030_0001493152-25-017373_ex99-1.htm:1]**

- InterCure Ltd. announced the **strategic acquisition of Botanico Ltd., also known as ISHI**, a premium medical cannabis technology and brand company, on September 19, 2025.  **[1857030_0001493152-25-014152_ex99-1.htm:0]** **[1857030_0001493152-25-014152_ex99-2.htm:0]** 
- This acquisition provides InterCure with **immediate access to advanced cultivation technologies** and established partnerships with leading American cannabis operators, including The Flowery, positioning InterCure to capitalize on the evolving U.S. cannabis market.  **[1857030_0001493152-25-014152_ex99-1.htm:0]** 
- The transaction is structured as a **two-phase acquisition of 100% of ISHI**, with the initial closing expected in **Q1 2026**, subject to regulatory approvals.  **[1857030_0001493152-25-014152_form6-k.htm:1]** **[1857030_0001493152-25-014152_ex99-1.htm:1]** 
- The **total consideration** for the acquisition is **4,513,663 ordinary shares** and **410,599 options** of InterCure, representing approximately **10%** of InterCure's outstanding shares on a fully diluted basis prior to the initial closing.  **[1857030_0001493152-25-014152_form6-k.htm:1]** **[1857030_0001493152-25-014152_ex99-1.htm:1]** 
- ISHI founders **Omer Layani (CEO) and Dor Hershkovitz (COO) will join InterCure's leadership team** as part of the acquisition.  **[1857030_0001493152-25-014152_form6-k.htm:1]** **[1857030_0001493152-25-014152_ex99-1.htm:1]**

Intercure (INCR)